Skip To Main Content

Cibisatamab (CEA x CD3)

(RG7802)

Gastrointestinal

Phase I

Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment

NCT04826003